Home  |  Archive  |  Online Submission  |  News & Events  |  Subscribe  |  APFA  |  Society  |  Links  |  Contact Us  |  中文版
Search
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

Links

Meetings
Journals
Societies & Institutes
Hospitals
Databases & Libraries
Companies
Websites
Other links

 
Abstract

Volume 15, Issue 3 (May 2013) 15, 356–357; 10.1038/aja.2012.166

The opportunity cost of androgen suppression in locally advanced prostate cancer

Phillip J Gray1,2, Jason A Efstathiou2 and William U Shipley2

1 Harvard Radiation Oncology Program, Boston, MA 02114, USA
2 Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA

Correspondence: Dr PJ Gray, (pjgray@partners.org)

Advance online publication 25 February 2013

Abstract

The use of androgen suppression therapy (AST) and radiotherapy for locally advanced prostate cancer has become the standard of care worldwide. At the same time, it has become clear that AST carries significant risk for side effects. Recently, Denham and colleagues have reported initial quality of life (QoL) results from the TROG 03.04 RADAR trial. The authors identify clinically meaningful decrements in patient-reported QoL for those treated with 18 months of AST vs. 6 months but only marginal differences at 36 months. Once survival data becomes available, these data will help to frame any benefits seen for longer courses of AST.

PDF |

 
Browse:  742
Copyright 1999-2014    Shanghai Materia Medica, Shanghai Jiao Tong University.    All rights reserved